@misc{misc, title = {{26880 Long-term efficacy and safety data for dupilumab in a phase 3, open-label extension trial (LIBERTY AD PED-OLE) in patients aged 鈮�6 to <12 years with uncontrolled, moderate-to-severe atopic dermatitis (AD)}}, url = {{}}, year = {{2021}}, month = {{9}}, author = {{Cork MJ and Tha莽i D and Eichenfield L and Arkwright PD and Chen Z and Delevry D and O鈥橫alley JT and Bansal A}}, note = {{Accessed on 2025/05/24}}}